Blood: Treating Refractable/Recurrent Non-Hodgkin's Lymphoma with CD19/CD20 CAR T Cells

The chimeric antigen receptor T (CAR T) cells targeted at CD19 have made breakthroughs in the treatment of malignancies in the hematologic system (e.g., recurrent/refractive non-Hodgkinlymphoma, r/rNHL);In this study, researchers designed a number of series CARs (TanCAR) and found that these TanCAR T cells not only exhibited dual antigen targets of CD19 and CD20, but also showed superior and stableimmunesynaptic (IS) structure, which may be related to their strong anti-tumor activityin the open one-arm Phase I/IIa trial (NCT030977770), the researchers recruited 33 r/rNHL patients, 28 of whom infusion TanCAR T cells after conditional chemotherapyThe main purpose is to assess the safety and tolerance of TanCAR T cellsSecondary objectives are to assess efficacy, progression-free survival and overall survival14 (50%) patients with cytokine release syndrome (CRS), of which 36% had level 1 or 2 and 14% had stage 3No CAR T-cell-related encephalopathy syndrome (CRES) of level 3 or above occursOne patient died from treatment-related severe lunginfectionthe overall mitigation rate ofwas 79 per cent and the total mitigation rate was 71 per centThe progression-free survival rate at 12 months was 64 per cent In this study, TanCAR7 T cells were used in r/rNHL patients to cause an effective and long-lasting anti-tumor response without level 3 and above CRES